Screener / SEC EDGAR /CIK 0001627223 /10-K filed Feb 24, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Chemicals & Allied Products

Chemours Co CC

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of CC's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Dec 13, 2023
Questions asked 71 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 7 UPLOAD
  2. 2. Questions in them 71 numbered comments
  3. 3. Company replies 7 CORRESP
  4. 4. Reviews closed 3 of 4 closing letter

Half the closed reviews took 28 days or less from the first letter to the closing letter.

Form 10-K

2023-12-13 to 2024-01-10 · 9 questions · 2 letters from the SEC, 2 from the company
Review closed 2024-01-10
Non-GAAP measuresResults discussion (MD&A)Liquidity and cashLegal and contingenciesInventorySegments
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 64
SEC asked (1)
We note the introduction into your presentation of non-GAAP measures, which refers to free cash flows (FCF) as a performance measure. We further note the reconciliation of FCF is from cash provided by operating activities, a liquidity measure.
Rest of the question

As such, please revise your disclosures provided in accordance with Items 10(e)(1)(i)(C) and 10(e)(1)(i)(D) of Regulation S-K to consistently characterize your presentation of FCF. Refer to Question 102.07 of the Compliance and Disclosure Interpretations for Non- GAAP Financial Measures for additional guidance. Address this comment and all other non-GAAP measure comments in both your period and current reports, as applicable.

CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that we will revise our disclosures regarding

FCF on future reports in accordance with Items 10(e)(1)(i)(C) and 10(e)(1)(i)(D) of Regulation S-K to clearly characterize FCF as a liquidity measure.
Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 64
SEC asked (2)
For each non-GAAP measure presented, please present the most directly comparable financial measure or measures calculated and presented in accordance with US GAAP in accordance with Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10(a) of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures.
Rest of the question

In this regard, we note your presentation of adjusted EBITDA margin, return on invested capital, and net leverage ratio without presenting the comparable margin, percentage or ratio calculated using the most comparable US GAAP measures.

CC answered
We acknowledge the

Staff’s comment and respectfully advise the Staff that the Company will exclude references to return on invested capital and net leverage ratio from our future Annual Reports on Form 10-K and Quarterly

Reports on Form 10-Q as these non-GAAP measures are not used in any discussions elsewhere in the Relevant Reports. We do, however, plan to continue presenting these non-GAAP measures in our earnings releases that will be furnished with a Current Report on Form 8-K.
Rest of the answer

As such, in future earnings releases, we will label these as non-GAAP measures, include a reconciliation of these non-GAAP measures from the most comparable US GAAP measures, and present the related GAAP measures with equal or greater prominence.

With respect to Adjusted EBITDA margin, we respectfully submit that our segment Adjusted EBITDA margin is not considered a non-GAAP measure. Adjusted EBITDA margin is presented in our MD&A at a reporting segment level and is not presented on a consolidated basis. Adjusted EBITDA margin is derived from our reporting segment operating measure of Adjusted EBITDA divided by reporting segment net sales to external customers. Each of these amounts is presented in the segment footnote to the financial statements as required by US GAAP in accordance with ASC 280, Segment Reporting. Accordingly, we do not believe a comparable US GAAP measure to the segment Adjusted EBITDA margin exists or is required to be presented in our MD&A.

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 64
SEC asked (3)
For your presentation of return on invested capital and net leverage ratio using non-GAAP measures, please revise the titles to clearly distinguish these measures as being based on non-GAAP measures rather than US GAAP measures. Refer to Item 10(e)(1)(ii)(E) of Regulation S-K for guidance.
CC answered
We acknowledge the Staff’s comment. As noted above in our response to the Staff’s second comment, we will exclude references to return on invested capital and net leverage ratio from our future Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as those non-GAAP measures are not used in any discussions elsewhere in the Relevant Reports.
Rest of the answer

We do, however, plan to continue presenting these non-GAAP measures in our earnings releases that will be furnished with a Current Report on Form 8-K and as such, in future earnings releases, we will clearly distinguish these measures as being based on non-GAAP measures and we will include a reconciliation of these non-GAAP measures from the most comparable

US GAAP measures in those furnished reports.

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 64
SEC asked (4)
Please revise your reconciliation of Adjusted EBIT to begin with the most comparable US GAAP measure rather than another non-GAAP measure. Refer to Item 10(e)(1)(i)(B) of Regulation S-K and Question 102.10(b) of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures for guidance.
CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that the Company will exclude references to Adjusted EBIT from our future Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

We do, however, plan to continue presenting Adjusted EBIT in our earnings release that will be furnished with a Current Report on Form 8-K and, as such, in future earnings releases, we will include a reconciliation of Adjusted EBIT from the most comparable US GAAP measures in those furnished reports.

Form

10-Q for the Fiscal Quarter Ended September 30, 2023

Item 2.
Rest of the answer

Management’s Discussion and Analysis of Financial Condition and Results of Operations Non-GAAP Financial Measures, page 73

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 73
SEC asked (5)
Please expand the footnote disclosures you provide for the adjustments to discuss all material components and to quantify each component discussed. For example, footnote 5 for the litigation-related charges of $675 million for the nine-months ended September 30, 2023, refers to litigation settlements, PFOA drinking water treatment accruals, and related legal fees with a reference to Note 17.
Rest of the question

However, Note 17 discloses that $592 million was recognized within selling, general and administrative expenses during the nine-months ended September 30, 2023, which leaves $83 million of the adjustment unexplained and/or unquantified.

CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that the Company will expand the disclosures in our footnotes to our non-GAAP reconciliation tables to discuss and quantify material components of the adjustments in our future

Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

For example, regarding footnote 5 to the table setting forth a reconciliation of our net income (loss) attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS, we will revise the relevant footnote in our future Annual Reports on Form 10-K and Quarterly Reports
Rest of the answer

on Form 10-Q to discuss and quantify material components of the adjustments to litigation-related charges. We have provided an example of the revised footnote below for the nine months ended September 30, 2023:

Page Five

Litigation-related charges pertain to litigation settlements, PFOA drinking water treatment liabilities, and related legal fees. For the nine months ended September 30, 2023, litigation-related charges included $592 million of charges related to the United States Public Water System Class Action Suit Settlement plus $24 million of third-party legal fees directly related to that settlement, $58 million for other PFAS litigation matters, and $1 million of other litigation settlements. For the nine months ended September 30, 2022, litigation-related charges

(gains) include proceeds from a settlement in a patent infringement matter. Refer to “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further details.

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 73
SEC asked (6)
We note that you are now referring to environmental remediation expenses that are adjusted as non-recurring. Please remove this characterization of this adjustment or explain how you were able to conclude this characterization is appropriate given that this is an adjustment made every period presented.
Rest of the question

Refer to Item 10(e)(1)(ii)(B) of Regulation S-K and Question 102.03 of the Compliance and Disclosure Interpretations for Non- GAAP Financial Measures for guidance.

CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that the Company will remove the “non-recurring” characterization of this adjustment in our future reports.
Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 73
SEC asked (7)
We note that you have included $28M for the write-off of certain raw materials inventory within the restructuring, asset-related and other charges adjustment for the nine-months ended September 30, 2023. With reference to ASC 420-10-S99-3, please tell us your consideration of the guidance in Question 100.01 the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures for this portion of the
Rest of the question

adjustment.

CC answered
We respectfully advise that the Company has considered the guidance set forth in

Question 100.01 of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures. The decision to write off $28 million of raw materials inventory, which was included in the Interim

Consolidated Statement of Operations as a component of Cost of Goods Sold, was a direct result of the decision to shut down the Company’s manufacturing site in Kuan Yin, Taiwan, which is in line with the Company’s strategic initiative to improve the earnings quality of the Titanium Technologies segment.
Rest of the answer

This action resulted in the Company incurring asset impairment and write-offs (including the raw materials inventory in question), severance costs, contract termination costs and decommissioning and dismantling charges. The raw materials write-off primarily consisted of $22 million of ore minerals and $6 million of other raw materials and packaging that are used in the production of the Company’s various TiO2 products. The Company’s Kuan Yin production plant was designed to use ore minerals of specific grade to produce specific TiO2 products that our Titanium Technology segment sells to customers in Asia

Pacific and are not economically interchangeable with the ore minerals we typically consume at other production sites. The $28 million raw materials inventory write-off, as noted above, does not include any TiO2 finished goods inventory that were still available for sale at the time of shutdown, as we expected that inventory to be recovered under normal sales. Absent the decision to shut down our manufacturing site in Kuan Yin, these types of charges are not expected to occur or would be very infrequent, if at all, and unusual for our Company as an industrial chemical manufacturer. Our historical raw materials adjustments are generally related

Page Six to production yield and not due to obsolescence or lower of cost or market adjustments. The Company believed, based on our facts and circumstances, the action taken to write off certain of our raw materials inventory at our Kuan Yin site as a result of a shutdown was not indicative of the market conditions and valuation of similar ore minerals, nor the Company’s ability to sell TiO2 products manufactured at our various sites.

Although the Company believes that its inventory adjustments in its presentation of non-GAAP financial measures were appropriate under the circumstances and not misleading (for reasons discussed above), we acknowledge the Staff’s comment and will exclude this type of adjustment from our non-GAAP performance measures in our future reports.

We also respectfully wish to inform the Staff that, in addition to excluding the $28 million raw materials inventory write off from our non-GAAP performance measures in future reports, we will exclude an immaterial charge of $8 million related to the write-off of stores inventory which was also included in the non-GAAP adjustment line item Restructuring, asset-related, and other charges. Our accounting policies classify “stores” as inventory. This inventory includes maintenance materials, operating supplies, spare parts including extra machinery and operating/service spare parts, which normally does not become an integral part of our finished product. By its nature, this is used for planned and operating maintenance of our manufacturing assets. Absent specific US GAAP guidance, we classify

“stores” as inventory for financial reporting purposes. Similarly, the Company has considered the guidance set forth in Question 100.01 of the Compliance and Disclosure Interpretation for Non-GAAP

Financial Measures and believes that, based on the nature of stores inventory and that the write-off was directly as a result of the decision to shut-down the Company’s manufacturing site in Kuan Yin,

Taiwan, excluding this type of cost from the non-GAAP performance measures is appropriate and not inconsistent with the guidance in Question 100.01, and with reference to ASC 420-10-S99-3 is also appropriate to be included in restructuring, asset-related and other charges. Although the Company believes that including stores inventory write-off in its presentation of non-GAAP financial measures was appropriate under the circumstances and not misleading (for reasons discussed above), consistent with the

Staff’s comment, we respectfully inform the staff that we intend to exclude stores inventory write-off in its presentation of Adjusted EBITDA.

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 73
SEC asked (8)
We note your presentation of adjusted free cash flows beginning in the September 30, 2023 Form 10-Q. Please tell us how you concluded that adjusting FCFs for PFAS litigation settlements is consistent with the guidance in Item 10(e)(1)(ii)(A) of Regulation S-K.
CC answered
We acknowledge the Staff’s comment and respectfully advise that the Company has considered the guidance set forth in

Item 10(e)(1)(ii)(A) of Regulation S-K. Adjusted free cash flow is a non-GAAP financial measure that represents cash that is available to the Company to fund operating activities after investing in its asset base, and litigation settlements and fees related to PFAS and PFOA matters.
Rest of the answer

When determining the nature of items to be adjusted from cash provided by

Page Seven operating activities for purposes of calculating adjusted free cash flow, the Company identifies items that are significant, unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of our business nor reflect the ongoing underlying cash generation of our businesses and on-going liquidity position. The change was driven by certain PFAS related settlements and directly related legal fees that we believe were unusual in nature or infrequent in occurrence that neither related to the Company’s ordinary course of business nor the underlying cash generation of our businesses. The Company believes that excluding items of this nature provides the Company’s investors with a better understanding of, and enables them to compare, the underlying cash generation of our businesses and our underlying liquidity from period to period.

In future reports, we will remove the presentation of Adjusted FCF from our Annual Reports on Form 10-K and Quarterly

Reports on Form 10-Q. We do, however, plan to continue presenting Adjusted FCF in our earnings releases that will be furnished with a Current Report on Form 8-K, together with the disclosure that fully describes the material components of the adjusted item(s) as well as a reconciliation of Adjusted FCF from the most comparable GAAP measure.

* *

*

Page Eight

If you require additional information or have any questions about this letter, please do not hesitate to contact me at [email protected] or (302) 773-3960 or our Chief Accounting Officer, Camela T. Wisel, at [email protected] or (302) 773-3234.

Read in the reply
In its next report

First report after the company's reply of Dec 22, 2023: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked
We note your response to prior comment 2 regarding your presentation of adjusted EBITDA margin only at the segment level as your segment profit measure. However, we note within the Segment Financial and Operating Data section of your earnings press releases that you include the presentation of adjusted EBITDA margin at the consolidated level.
Rest of the question

As such, we continue to request that you present the most directly comparable financial measure or measures calculated and presented in accordance with US GAAP in accordance with Item 10(e)(1)(i)(A) of S-K.

CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that, in future reports, we will remove the presentation of Adjusted EBITDA margin at the consolidated level in our earnings releases that will be furnished with a Current Report on Form 8-K.

Division of Corporate Finance

Page Two

* *

*

If you require additional information or have any questions about this letter, please do not hesitate to contact me at [email protected] or (302) 773-1000 or our Chief Accounting Officer, Camela T. Wisel, at [email protected] or (302)

773-3234.
Read in the reply
In its next report

First report after the company's reply of Jan 8, 2024: 10-K filed Mar 27, 2024 ↗, against the 10-K filed Feb 10, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-01-10

Form 10-K for the year ended December 31, 2019

2020-03-13 to 2020-04-01 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-04-01
Revenue
Note 3. Summary of Significant Accounting Policies · Revenue Recognition, page F-11
SEC asked
We note your disclosure that you also license the right to access certain trademarks to customers and that under such arrangements, you may receive a royalty payment for a trademark license that is entered into on a standalone basis or incorporated into an overall product arrangement.
Rest of the question

We further note that in instances that no consideration is specified for the use of your trademark, the entire transaction price is recognized in connection with the transfer of control of the product. Please tell us and further expand your disclosures to highlight the following: • The typical terms of your arrangements that include the sale of a license for the right to access your trademarks. Please highlight whether such arrangements include additional consideration in addition to the sales and royalties you may receive; • Whether you view the sale of the license for the right to access the trademarks as distinct and its own performance obligation when included in a contract for a sale of product. See ASC 606-10-55-55; • Whether you are recognizing revenue related to the sale of such licenses over time, and if you have determined that such licenses are not considered their own performance obligations, how you considered the guidance in ASC 606-10-55-57 for recognizing revenue for the combined unit; Finally, please clarify the amount of revenue you have recognized in net sales as it relates to arrangements that include sales of such licenses for each of the periods presented. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

CC answered
Securities and Exchange Commission

We acknowledge the Staff’s comment and further clarify that, under Accounting Standards Codification (“ASC”) Topic 606, the Company’s revenue from trademark licenses with customers amounted to $4 million and $4 million for the years ended December 31, 2019 and 2018, respectively. Such amounts comprised less than 0.1% of the Company’s net sales for each of the respective years. Effective January 1, 2018, the Company adopted Accounting Standards Update No.
Rest of the answer

2014-09, Revenue from Contracts with Customers, as well as the subsequent clarifying updates in connection with the standard as issued by the Financial Accounting Standards Board (collectively, “Topic 606”) utilizing a practical expedient allowed under the modified retrospective transition method. Prior to the Company’s adoption of Topic 606, $2 million of trademark license income from customers was included as a component of the “Other income (expense), net” line item in the Consolidated Statements of Operations for the year ended December 31, 2017. This amount would have comprised less than 0.1% of the Company’s net sales for the year ended December 31, 2017.

The extent of the Company’s existing disclosures related to trademark license revenues were made with a view to the level of immateriality of trademark license revenue/income relative to the Company’s overall financial results.

Chemours generates trademark license revenue from its arrangements with customers as defined by Topic 606, which involve licensing a Chemours brand in an arrangement that may be royalty or non-royalty bearing with a Chemours customer who purchases tangible products. Such arrangements are generally executed as a standalone license agreement based on an existing Chemours product sales relationship. These license agreements can be negotiated separately from or contemporaneously with the formation of product sales arrangements with that customer. Royalties received from trademark license arrangements typically vary based on sales and may be received over a fixed period of time or in perpetuity. Amounts may vary based upon the specific brand licensed, the product’s standard use, the applicable geographical region, and the customer’s attributes; however, royalties earned under trademark license agreements with customers are individually and collectively immaterial to the Company’s net sales, and no additional consideration outside of product sales and royalty payments is received.

The Company enters into trademark license agreements with its customers, as well as other third-party licensees that utilize a Chemours brand for marketing purposes. Such third-party licensees are typically customers of Chemours’ customers, comprised of retailers who do not purchase tangible products directly from Chemours. Prior to the Company’s adoption of Topic 606, royalties earned from trademark license agreements with both customers and other third-party licensees were reported as a component of the “Other income (expense), net” line item in the Company’s Consolidated Statements of Operations, as the license of trademarks had not been viewed as part of Chemours’ major or central ongoing operations under ASC Topic 605. However, with the adoption of Topic 606, which introduced explicit guidance related to licensing arrangements, we further considered whether certain license arrangements represented contracts with a customer and would therefore be within the scope of Topic 606. Based upon our assessment, we concluded that the Company’s ordinary business activities relate to selling performance chemicals rather than trademark licensing arrangements, exclusive of product sales. Accordingly, we do not consider the aforementioned third-party licensees to have met the definition of a customer as set forth by ASC 606-10-20, and as such, royalties earned from these trademark license agreements are considered to be outside the scope of Topic 606. Royalties from such arrangements represent an individually and collectively immaterial income stream for the Company, and we continue to recognize such amounts as a component of the “Other income (expense), net” line item in the Company’s Consolidated Statements of Operations. However, pursuant to Topic 606, when license income relates directly to the sale of a product (i.e., license for a customer to use the brand associated with the product), that license is a contract with a customer, and the associated royalties are reported as a component of “Net sales” in the Company’s Consolidated Statements of Operations.

As a first step in identifying performance obligations in contracts with customers, Topic 606 requires the Company to identify, at contract inception, the promised goods and services in the contract. Such promised goods and services can be explicitly stated in the contract or can be implied by a company’s customary business practices. We consider the trademark license granted to a customer to be a promise in a contract. Under ASC 606-10-55-55, when a contract with a customer includes a promise to grant a license in addition to other promised goods or services, an entity applies paragraphs 606-10-25-14 through 25-22 to identify each of the performance obligations in the contract.

We considered the guidance as set forth in ASC 606-10-25-19 through 25-21 in determination of whether such a promise should be considered a distinct and separate performance obligation when compared to the promise to transfer goods under the associated product sales. More specifically, in consideration of the factors indicating non-separately identifiable promises as outlined in ASC 606-10-25-21(c), where a trademark license agreement is entered into separately or incorporated into an overall product sales arrangement, whether royalty-bearing or not, the license of the trademark is made based on the product sale relationship and is highly interrelated to product sales. From the customer’s perspective, the trademark has no use or value without purchases of the product, and the ability to utilize the trademark improves the ability to sell the final product to an end customer. While the license is not integral to the functionality of the good (i.e., underlying product), the license can only provide benefit in conjunction with the related product. From Chemours’ perspective, receipt of royalties on the trademark license is wholly dependent on continuing product sales to the customer. Therefore, we consider the trademark licenses not to be distinct within the context of the contract. ASC 606-10-55-56 states that if a promise to grant a license is not distinct from other promised goods or services in the contract, an entity should account for the promise to grant a license and those other promised goods or services together as a single performance obligation.

Under Topic 606, the Company’s trademark licenses meet the definition of Symbolic Intellectual Property, and the Company performs ongoing activities (e.g., marketing) to support and maintain this intellectual property. Revenue from Symbolic Intellectual Property is typically recognized over the license period; however, given that the Company’s trademark license revenues are not representative of a distinct performance obligation, these revenues are recognized as a bundle of the license and the products sold. When applying ASC 606-10-55-57 in such instances requiring revenue recognition for a combined unit, management judgment is required in assessing the nature of the promise and the overall significance of the license to the product in the bundled arrangement. We concluded that trademark licenses are incidental to the product/trademark license bundle. Therefore, where a sales-based royalty is included in the transaction price, and given the inherent difficulty in estimating variable consideration as prescribed by ASC 606-10-32-5, the Company applies the exception outlined in ASC 606-10-55-65 in recognizing variable sales-based royalties as the subsequent sale of the customer’s product occurs.

For disclosure purposes, we considered whether disaggregation of revenue between product sales and the customer’s right to access trademark licenses would be a meaningful disclosure. We concluded that, based on the immateriality of the trademark license revenue stream, as well as the fact that the license is considered incidental to the product/trademark license bundle, this is not a distinction that is utilized to evaluate financial performance or make resource allocation decisions. Therefore, such disaggregation was not considered necessary for our financial statement disclosures.

Read in the reply
In its next report

First report after the company's reply of Mar 26, 2020: 10-Q filed May 6, 2020 ↗, against the 10-Q filed Nov 5, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-04-01

Form 10-K for the Fiscal Year Ended December 31, 2015

2016-05-23 to 2016-06-29 · 15 questions · 1 letter from the SEC, 1 from the company
Review closed 2016-06-29
Results discussion (MD&A)Income taxesLiquidity and cashNon-GAAP measuresGoodwill and impairmentDebtRevenueSegmentsPensionsLegal and contingencies
Recent Developments, page 38 · Transformation Plan, page 38
SEC asked (1)
We note that you expect the transformation plan to deliver $500 million of incremental Adjusted EBITDA improvement over 2015 through 2017. Please disclose your expected GAAP cost savings. Ensure future filings address whether your actual results are in line with the anticipated cost savings. If the anticipated savings are not achieved as expected, ensure your disclosures address the reasons for the differences.
Rest of the question

Please refer to SAB Topic 5:P.4 for guidance. Results of Operations, Page 40 (Benefit from) provision for income taxes, page 42

CC answered
to the Staff’s comment, in our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will include within the Transformation Plan discussion of our MD&A the following:

“Based on our anticipated cost reduction and growth initiatives, we expect that our cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives will also improve our pre-tax earnings by similar amounts through 2017.”

Also, we will clarify whether our actual results are in line with anticipated improvements from cost savings
Rest of the answer

and growth initiatives for the applicable fiscal year. In addition, although we anticipate that we will achieve our estimated cost savings and growth initiatives through 2017, we will address in our future filings if these anticipated benefits are not achieved.

Results of Operations, Page 40

(Benefit from) provision for income taxes, page 42

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Recent Developments, page 38 · Transformation Plan, page 38
SEC asked (2)
Please revise your disclosure to better explain your changes in your income tax (benefit) and expense. In this regard, based on your reconciliation on page F-12, it is unclear how your effective tax rate was increased by tax benefits recognized from the restructuring and asset impairments in the U.S. Please also explain how the increase in the effective tax rate was offset by earnings in foreign subsidiaries.
Rest of the question

In this regard, it appears from your reconciliation on page F-21 that the benefit from (lower effective tax rate) on international operations was more significant in 2015 than 2014.

CC answered
to the Staff’s comment, we will include in our next Annual Report on Form 10-K for the year ended December 31, 2016 the following disclosure to clarify and better explain the changes in our income tax (benefit) and expense in 2015 and 2014 as follows:

“For the years ended December 31, 2015 and 2014: For the year ended December 31, 2015, Chemours recorded a tax benefit of $98 million with an effective income tax rate of approximately 52%. For the year ended December 31, 2014, Chemours recorded a tax provision of $149 million with an effective tax rate of approximately 27%.
Rest of the answer

The $247 million decrease in the tax provision was related to the $738 million decrease in income before income taxes. This decrease in income before income taxes was primarily due to continued pressure on TiO2 prices, soft demand conditions for certain fluoropolymers products, and restructuring and asset impairment charges. Although the earnings in our foreign operations remained consistent for the years ended December 31, 2015 and 2014, the earnings in the U.S. were impacted by the aforementioned factors. The mix of geographical earnings resulted in the effective tax rates varying between 2015 and 2014.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Titanium Technologies, page 43
SEC asked (3)
Please expand your disclosures to provide better insight into the significant decrease in Adjusted EBIDTA and Adjusted EBITDA margins. In this regard, quantify the changes of the items you identified as drivers of the decrease in these measures as well as those items that offset these negative drivers.
CC answered
to the Staff’s comment, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will clarify and quantify the material changes in our Adjusted EBITDA to provide additional clarity with respect to the factors impacting our Titanium Technologies segment results. We will also include in our next Annual Report on Form 10-K for the year ended December 31, 2016 the following disclosure to quantify the significant changes in Adjusted EBITDA for the Titanium Technologies segment in 2015 as follows (language in bold fonts are additions made to the previously disclosed
Rest of the answer

paragraph):

“Adjusted EBITDA decreased by 55% during the year ended December 31, 2015 in comparison with the same period in 2014. Adjusted EBITDA margin also decreased during the year ended December 31, 2015 in comparison with same period in 2014. The decreases were primarily driven by lower sales and margin which contributed to an approximately 39% decrease in Adjusted EBITDA due to lower prices, and unfavorable effects of foreign currency which contributed to an approximately 19% decrease in Adjusted EBITDA. Partially offsetting these decreases were productivity improvement initiatives, which resulted in lower raw materials, energy and plant operating costs, as well as the impact of our cost reduction programs, which included certain Titanium Technology plant shut-downs and global headcount reductions.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Liquidity and Capital Resources, page 45
SEC asked (4)
We note that you have foreign operations and unremitted earnings of subsidiaries outside of the U.S. for which you have not provided deferred income taxes. To the extent applicable and material, please revise future annual and quarterly filings to address the following:  Disclose the amount of cash and cash equivalents held by foreign subsidiaries as of the most recent balance sheet date presented; and  Discuss
Rest of the question

the potential tax implications if such funds are needed for operations in the U.S.

CC answered
to the Staff’s comment, we will include in our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, disclosure of the amount of foreign cash and cash equivalents, to the extent material, under the heading “Liquidity and Capital Resources.” The revised disclosure will also include financial information as of June 30, 2016 and December 31, 2015, as follows:

“As of June 30, 2016 and December 31, 2015, we had $[ ] million and $271 million of cash and cash equivalents on our balance sheet held by our foreign subsidiaries, all of which is readily
Rest of the answer

convertible into currencies used in the Company's operations, including the U.S. dollar. Cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At June 30, 2016 and December 31, 2015, management believed that sufficient liquidity was available in the United States, and it is the Company's intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries outside of the United States. No deferred tax liabilities have been recognized with regard to the approximately $[ ] million and $271 million of cash of our foreign subsidiaries as of June 30, 2016 and December 15, 2015, respectively, and undistributed earnings. Potential tax implication of the repatriation of unremitted earnings are driven by facts at the time of distribution therefore it’s not practicable to estimate the income tax liabilities that might be incurred if such earnings were remitted to the U.S.”

Although we have no intention to repatriate the undistributed earnings of our foreign subsidiaries at present, if such funds are needed for operations in the U.S., to the extent applicable and material, the Company will revise future annual and quarterly filings to address the potential tax implications.

Supplementally, we note that at March 31, 2016 the amount of cash and cash equivalents held by our foreign subsidiaries was $260 million, and the Company's indefinite reinvestment assertion was described within Item 7 of the Form 10-K under header Critical Accounting Policies and Estimates - Income Taxes.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financing Transactions, page 47
SEC asked (5)
We note that you entered into amendments to your Revolving Credit Agreements in the third quarter of 2015, as well as the first quarter of 2016. Please expand your disclosures regarding the credit facility to address each of the following:  An explanation of the specific factors that prompted the need to amend the credit facility in the third quarter of 2015 and then again in the first quarter of 2016;  A more
Rest of the question

specific discussion of the covenants you needed relief from;  A discussion of the impact of reducing the credit facility by $250 million to $750 million and your conclusion that your operations and debt financing arrangements will provide sufficient liquidity over the next 12 months; and  A discussion of the impact to your consolidated financial statements and business if you are unable to meet the amended debt covenants. Please refer to Item 303(a)(1) of Regulation S-K, Instruction 5 to Item 303(a) of Regulation S-K, and Section 501.13 of the Financial Reporting Codification for guidance.

CC answered
to the Staff’s comment, in our future filings beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will revise our disclosure under the “Liquidity and Capital Resources” section to expand the discussions of the amendments to our credit agreement as follows:

“In September 2015, in connection with the Company's transformation plan announced in August 2015, the Company undertook a first amendment to the credit agreement to allow pro forma inclusion of future benefits from cost savings initiatives in the calculation of financial covenants that rely on
Rest of the answer

consolidated EBITDA beginning from the quarter ended September 30, 2015. Since the revolver availability in any quarter is determined by the cushion remaining in the financial maintenance covenants at the end of the previous quarter, this amendment increased the Company's access to its revolving credit facility.

In February 2016, the Company proactively pursued a second amendment to the credit agreement in order to ensure that it would retain adequate liquidity and sufficient cushion in the event of an unexpected, further significant decline in TiO2 pricing. The second amendment also provided further flexibility by allowing the Company to include, on a pro forma basis, future benefits of cost savings initiatives in the calculation of financial covenants that rely on consolidated EBITDA for an additional year, and increased the amount of the applicable cost savings benefits that could be utilized in the covenant calculation. In addition, the second amendment replaced the total net leverage ratio with the senior secured net leverage ratio and modified the minimum required levels of the interest expense coverage ratio. These changes were designed to allow the Company to have full access to the revolving credit facility, provide flexibility to execute its transformation plan through 2017 and provide additional cushion in the event of an unexpected, further significant decline in TiO2 pricing. Furthermore, the amendment reduced the size of the revolving credit facility by $250 million to $750 million. With the on-going efforts to improve working capital usage as a part of our transformation plan, we believe that $750 million of revolver access will be sufficient to meet our working capital and other cash needs over the next 12 months.

In the event of a default under the revolving credit facility, our lenders under the revolving credit facility can terminate their commitments thereunder, cease making further revolving loans and accelerate outstanding revolving loans. This would allow the lenders under the revolving credit facility to declare the outstanding term loans to be immediately due and payable and to institute foreclosure proceedings against the collateral securing the credit facility, which could force us into bankruptcy or liquidation. Any event of default or declaration of acceleration under the credit agreement also may result in an event of default under the indenture governing the notes. Any such default, event of default or declaration of acceleration could materially and adversely affect our results of operations and financial condition. Please see the section titled “Risks Related to our Indebtedness” of the “Risk Factors” section of the Form 10-K for additional detail.”

Supplementally, in response to the Staff's comments, we inform the staff that average global TiO2 prices currently are at levels above December 31, 2015. With respect to the impact of the $250 million reduction in the credit facility on our liquidity, we inform the Staff that the Chemours business is subject to seasonality, with working capital as a use of cash in the first half of the year, and working capital as a source of cash in the second half of the year. Prior to our separation from DuPont, a $1 billion revolver was negotiated to preserve the Company's ability to fund its working capital requirements without any other external borrowing. However, as disclosed in our Quarterly Report on Form 10-Q for the periods ended on June 30, 2015 and September 30, 2015, the Company did not have full access to the revolver due to the restrictions imposed by the financial maintenance covenants. The second amendment provided full access to the revolver even though its size was reduced from $1 billion to $750 million. We believe a revolving credit facility of this size provides adequate liquidity for all of the Company’s potential cash needs. We drew funds from our revolver only once in 2015, which were fully repaid shortly thereafter.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financing Transactions, page 47
SEC asked (6)
We note that you were in compliance with your debt covenants as of December 31, 2015. If it is reasonably possible that you may violate a material debt covenant(s), please disclose your actual amounts/ratios as of each reporting date in addition to the required amounts/ratios. This will allow readers to understand how much cushion there is between your actual amounts/ratios and the required amounts/ratios.
Rest of the question

Please consider showing the specific computations used to arrive at the actual amounts/ratios. See Sections I.D and IV.C of the SEC Interpretive Release No. 33-8350.

CC answered
At December 31, 2015, under the then existing credit agreement, the Company was in full compliance with its covenants. Prior to the second amendment to the credit agreement, the Company was required to maintain a total net leverage ratio of not more than 5.75 to 1.00 and a minimum interest expense coverage ratio of 3.00 to 1.00.
Rest of the answer

The Company's actual ratios as of December 31, 2015 were 4.98 to 1.00 and 3.30 to 1.00, respectively.

The second amendment to the credit agreement became retroactively effective on December 31, 2015, and among other things, replaced the total net leverage ratio covenant with the senior secured net leverage ratio covenant of not more than 3.50 to 1.00 for each quarter through December 31, 2016, and modified the minimum required levels of the interest expense coverage ratio to 1.75 to 1.00 each quarter through June 30, 2017. Our senior secured net leverage ratio and interest expense coverage ratio as of December 31, 2015 were 1.52 to 1.00 and 3.34 to 1.00, respectively.

As of March 31, 2016 and based upon our current outlook through the remainder of 2016, the Company continues to believe that it is not reasonably possible that a violation of a material debt covenant will occur.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Cash Flow, page 46
SEC asked (7)
You indicate that one of your primary sources of your liquidity is cash flows from operations. Please address the fact that there has been a significant negative trend in your cash flows from operations since 2011, which has continued through 2015.
CC answered
to the Staff’s comment, in our future filings beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will include additional discussion of our operating cash flows as follows:

“Chemours’ operating cash flow generation is driven by, among other things, global economic conditions generally and the resulting impact on demand for our products, raw material and energy prices, and industry-specific issues, such as production capacity and utilization.
Rest of the answer

Chemours has generated strong operating cash flow through various industry and economic cycles evidencing the operating strength of our businesses. Over the industry cycles in recent years, cash flows from operating activities increased in years leading up to the historical peak profitability achieved in 2011, and have decreased annually since that time. Despite the challenging market conditions in the TiO2 industry since the historical peak profitability in 2011, we anticipate that through our cost reduction efforts and growth initiatives, our operations will provide sufficient liquidity to implement the transformation plan and support cash needs for the business.”

Supplementally, we note that while the Company experienced lower operating cash flows during 2015, which was a significant decline when compared to prior years, the Company drew from its revolver only once, which draw was repaid in full shortly thereafter. After the separation from DuPont, management's focus on cost reduction, growth initiatives and working capital improvements has helped drive improvements in our operating cash flows. We expect to generate modestly positive operating cash flows in 2016 driven by improvements in TiO2 pricing, growth from OpteonTM and improvements in our working capital. In our future filings, we will further clarify these expectations in the Outlook discussion of our MD&A.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Measures, page 56
SEC asked (8)
Please revise future filings to define “non-operating pension and other postretirement employee benefit costs” and the reason for its exclusion in the calculation of adjusted net income and adjusted EBITDA.
CC answered
to the Staff’s comment, we will revise our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, to define “non-operating pension and other postretirement employee benefit costs”, which represents “the components of net periodic pension costs (income) excluding service cost component”.
Rest of the answer

Such costs (income) were excluded from Adjusted EBITDA because management, including our CODM, believes that these costs (income) are not indicative of the ongoing operational performance of our business segments as these costs are not driven by business operations but rather are based on certain actuarially determined assumptions (e.g. interest rates) that are subject to changes year over year.

As described on page 57 of the Form 10-K, Part II Item 7 - Non-GAAP Financial Measures, “We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income and Free Cash

Flow should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items.”

We do not believe these costs (income) represent the underlying value of ongoing operations. As such, these non-operating components of pension cost and other adjustments were excluded from Adjusted EBITDA to enable an investor to better assess our underlying operating performance.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 3. Summary of Significant Accounting Policies, page F-9 and · Note 8. Income Taxes, page F-20
SEC asked (9)
We note that your $32 million reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations, as well as your $36 million release of the valuation allowance, were both related to the DuPont tax matters agreement. Please tell us supplementally and revise to clarify how these adjustments impacted your results of operations, if at all.
Rest of the question

Specifically address why these adjustments do not appear to have impacted your effective tax rate.

CC answered
to the Staff's comment, we will revise our disclosures related to these matters in our next Annual Report on Form 10-K for the year ended December 31, 2016 as follows:

With respect to the $32 million unrecognized tax benefit on page F-22 of the Form 10-K footnote (1):

“Reduction to unrecognized tax benefits represents DuPont’s responsibilities for uncertain income tax positions recorded prior to July 1, 2015 pursuant to the tax matters agreement.
Rest of the answer

The reduction was recorded in "DuPont Company Net Investment" of the Consolidated Statements of Stockholders' Equity.”

With respect to the $36 million release of valuation allowance on page F-23 of the Form 10-K footnote (1):

“Release of valuation allowance during 2015 was related to tax loss carryforward incurred prior to July 1, 2015 that is attributable to DuPont’s tax periods pursuant to the tax matters agreement. The adjustment was recorded in "DuPont Company Net Investment" of the Consolidated Statements of Stockholders' Equity.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 6. Employee Separation and Asset Related Charges, Net, page F-17
SEC asked (10)
With reference to the property, plant and equipment and other asset impairment charges related to your Titanium Technologies Plant Closures, please revise your disclosure to indicate the method or methods you used in determining the fair values of the impaired assets and disclose the remaining carrying values of these assets. Refer to ASC 360-10-50 and ASC 820-10-50-5.
CC answered
We acknowledge the Staff’s comment and respectfully inform the Staff that the impairment recorded by our Titanium Technologies segment did not result from an impairment assessment of an asset group but rather an accelerated depreciation of its Edge Moor plant assets as a result of the Company’s decision in August 2015 to cease the production of TiO2 at its Edge Moor plant and shut down the plant effective in September 2015.
Rest of the answer

Given the timing of the decision and that the plant assets no longer provide economic benefits to the Company, the assets were substantially written off as of September 30, 2015. Therefore, we believe disclosure of the method or methods used in determining the fair values of the impaired assets as required by ASC 360-10-50 is not applicable. The remaining carrying values of the assets not written off were less than $1 million which was deemed not material for disclosure purposes. This represents primarily fixed assets that were and will be transferred to and used by another Titanium Technologies plant in the United States. In addition, salvage value was minimal due to the potentially substantial dismantling and clean-up cost necessary to bring the asset to a saleable condition. As a result, there was no amount to disclose as being recorded at fair value on a non-recurring basis at December 31, 2015.

We will revise our disclosure pertaining to Titanium Technologies Plant closures in our next Annual Report on Form 10-K for the year ended December 31, 2016 as follows (language in bold fonts are additions made to the previously disclosed paragraph), updated as necessary:

“In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing site located in the U.S. The Edge Moor plant produced TiO2 product for use in the paper industry and other applications where demand has steadily declined, resulting in underused capacity at the plant. In addition, the Company permanently shut down one underused TiO2 production line at its New Johnsonville, Tennessee plant. The Company stopped production at Edge Moor in September 2015 and immediately began decommissioning the plant. These actions resulted in the write-off of substantially all of the Edge Moor plant asset carrying value in 2015. The Company completed its decommissioning activities in the first quarter of 2016 and commenced dismantling the plant. Dismantling and removal activities are expected to be completed in early 2017.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 12. Property, Plant and Equipment, page F-25
SEC asked (11)
Please disclose the remaining carrying value of the RMS manufacturing facility. Refer to ASC 820-10-50-5.
CC answered
to the Staff's comment, we will revise in our next Annual Report on Form 10-K for the year ended December 31, 2016 the impairment discussion of the RMS manufacturing facility as follows (language in bold fonts are additions made to the previously disclosed paragraph):

“During the third quarter of 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, excluding cyanides, the Company determined that the carrying value of the RMS manufacturing facility of the Chemical Solutions segment may not be recoverable given the strategic decision to discontinue investment
Rest of the answer

in the business. An impairment evaluation was performed which indicated that the carrying amount of this asset group in the U.S. was not recoverable when compared to the expected undiscounted cash flows.

Based on management’s assessment of the fair value of the asset group, the Company determined that the carrying value of that asset group exceeded the fair value and, as a result, a $45 pre-tax impairment charge was recorded in the Chemical Solutions segment, which represents an impairment of substantially all of the remaining net book value of the RMS asset group. The fair value of the asset group was determined using an income approach based on the present value of the estimated future cash flows. The key assumptions used included growth rates and cash flow projections, discount rate, tax rate and an estimated terminal value. The amount was recorded in employee separation and asset related charges, net in the Consolidated Statements of Operations.”

We advise the Staff that after the impairment charge, the RMS manufacturing facility has substantially no remaining carrying value as the salvage value is minimal due to the potentially substantial dismantling and clean-up cost necessary to bring the asset to a saleable condition. As a result, there was no amount to disclose as being recorded at fair value on a non-recurring basis at December 31, 2015.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 19. Commitments and Contingencies, page F-31 · Litigation, page F-31
SEC asked (12)
Please reconcile your statement : “Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations
Rest of the question

or liquidity ,” with your following stat ement: “In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter, these indemnification claims could materially adversely affect Chemours' financial condition.” Please revise your disclosure as necessary to address this apparent contradiction.

CC answered
In our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will revise the cited litigation disclosure as follows (language in bold fonts are additions made to the previously disclosed paragraph):

“Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated
Rest of the answer

financial position, results of operations or liquidity. With respect to the litigation matters discussed below, including PFOA litigation, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter relating to PFOA, these indemnification claims could materially adversely affect Chemours' financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

PFOA, page F-32
SEC asked (13)
We note that during 2015 there were 600 claims filed in federal and state courts alleging personal injury against DuPont related to exposure to PFOA. Please revise your disclosure to include this information so that readers can assess the level of claims activity for each period presented.
CC answered
to the Staff’s comment, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will revise our disclosure on PFOA to include changes in the number of filed cases as follows (language in bold fonts are additions made to the previously disclosed paragraph):

“Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists.
Rest of the answer

At June 30, 2016 and December 31, 2015, there were approximately [ ] lawsuits and 3,500 lawsuits, respectively, filed in various federal and state courts in Ohio and West Virginia, an increase [or decrease] of approximately [ ] and 600 over year end 2014, respectively. These lawsuits are consolidated in multi-district litigation (MDL) in Ohio federal court.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 23. Geographic and Segment Information, page F-43
SEC asked (14)
We note that products are transferred between segments on a basis to reflect, as nearly as practicable, the market value of the products. Please revise your presentation of revenues by reportable segment to separately present revenues from external customers and revenues from transactions with other reportable segments in accordance with ASC 28010-50-22.
CC answered
We acknowledge the Staff’s comment and recognize the disclosure requirement under ASC 280-10-50-22. We respectfully inform the Staff that the Company did not include the revenues from transactions with other reportable segments because our CODM believes these revenue transactions are not significant to the overall understanding of Company’s consolidated and segment results of operations, and are not considered in making operating decisions.
Rest of the answer

For the years ended December 31, 2015, 2014 and 2013, total revenues from other reportable segments were $3 million, $7 million and $8 million, respectively. We expect this trend to continue. In the event the intersegment sales become material in future periods, we will disclose such amounts including the comparative information in prior periods.

In our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will revise our segment disclosure with reference to products transferred between segments as follows: “Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented.”

In addition, we will also revise the “Net sales” line on the segment financial table to “Net sales to external customers.”

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 23. Geographic and Segment Information, page F-43
SEC asked (15)
With reference to ASC 280-10-50-40, please provide revenues from external customers for each product and service or each group of similar products and services.
CC answered
In our future filings, beginning with our Quarterly Report on Form 10-Q for the period ended June 30, 2016, we will revise the “Net sales” line on the segment financial table to “Net sales to external customers.”

Also, we acknowledge that we disclosed on Item 1 Business section of the Form10-K our product groups.
Rest of the answer

We will include in our next Annual Report on Form 10-K for the year ended December 31, 2016 the net sales from external customers by product group as follows:

Year ended December 31,

2016

2015

2014

Titanium dioxide

$ [ ]

$

2,392

2,937

Fluoropolymers

[ ]

1,246

1,326

Fluorochemicals

984

1,001

Performance chemicals and intermediates

551

621

Cyanides

301

314

Sulfur

243

233

—

5,717

6,432

* * * * *

The Company hereby acknowledges to the Staff of the Division of Corporation Finance of the Securities and Exchange Commission that:

the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Jun 16, 2016: 10-Q filed Aug 9, 2016 ↗, against the 10-Q filed May 9, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2016-06-29

Form 10-12B

2015-02-26 to 2015-06-05 · 46 questions · 3 letters from the SEC, 3 from the company
No closing letter
Liquidity and cashResults discussion (MD&A)SegmentsRisk factorsIncome taxesDebtLegal and contingenciesClimateInventoryGoodwill and impairmentDerivatives and hedgingPensions
Form 10-12B · General
SEC asked (1)
Please refer to comment 1 in our letter dated January 14, 2014. Describe to us the items you sold to Syria in 2011 and 2012.
CC answered
We acknowledge the Staff’s comment and respectfully inform the Staff that Chemours had one shipment of Virkon® S disinfectant in each year 2011 and 2012 into Syria. Virkon® S is a disinfectant used on hard surfaces marketed to commercial livestock producers, farmers and veterinary hospitals to protect against numerous microorganisms. In 2011 there was also one shipment of Ti-Pure® titanium dioxide, which is marketed for use in coatings, plastics, laminates and paper products end markets, into Syria.
Read in the reply
Form 10-12B · General
SEC asked (2)
Please revise your registration statement to provide updated financial statements and related disclosures as required by Rule 3-12 of Regulation S-X.
CC answered
to the Staff’s comments, the Company respectfully advises the Staff that the Company has updated all financial information and related disclosures through December 31, 2014 in accordance with Item 3-12 of Regulation S-X.
Read in the reply
Exhibit 99.1 · Information Statement Summary, page 1
SEC asked (3)
We note that you have not provided any discussion of the risks faced by your company, other than a reference to your risk factors before the summary begins, and that you have not revised your summary to provide a more balanced presentation of your company.
Rest of the question

We further note that you do not provide any discussion regarding the challenges raised by or impact of your planned debt and credit rating, the cash distribution you will be making to DuPont, or your environmental liabilities. Please note that when we referenced these in comment 3 of our letter dated January 14, 2015 they were only examples. Please revise.

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 9–10.
Read in the reply
Our Strengths, page 2 · Strong Cash Flow Generation, page 5
SEC asked (4)
We note your response to comment 4 of our letter dated January 14, 2015 and the revision to your disclosure; however, as requested in our prior comment, please expand your discussion of your operating cash flows to convey the fact that notwithstanding the fact that you have generated strong operating cash flows, these cash flows have been declining since 2011.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 5 and 78.
Read in the reply
Risk Factors, page 19 · As a substantial percentage of our operations are conducted internationally, and we plan to grow … page 20
SEC asked (5)
Please provide a discussion of the risks posed to your business by its current activities in Asia, Eastern Europe and Latin America, as well as your properties in those areas. Please also provide a discussion of the risks posed by your expansion plans in these areas. Please refer to comment 6 of our letter dated January 14, 2015.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 21.
Read in the reply
The Distribution, page 36 · Conditions to the Distribution, page 40
SEC asked (6)
We note your supplemental response to comment 12 of our letter dated January 14, 2015. Please revise to disclose what notice will be given to shareholders if a condition is waived, amended, modified or if the spinoff is abandoned by DuPont.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages

16, 43 and 151.
Read in the reply
Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (7)
We note your revised disclosure on page 59 in response to comment 14 of our letter dated January 14, 2015. You currently provide a single sentence discussing trends and uncertainties that may prospectively affect one of your three segments.
Rest of the question

Please revise to provide a more thorough indication of management’s views regarding the trends and uncertainties that you reasonably expect may materially impact your results of operations.

CC answered
to the Staff’s comment, the Company has revised its disclosures related to Segment results beginning on pages 60 and 61–62.
Read in the reply
Overview
SEC asked (8)
We note your revised disclosures provided in response to comment 15 of our letter dated January 14, 2015. We note that your manufacturing processes consume significant amounts of ore materials, hydrocarbons and energy which are dependent on oil and gas pricing. The cost of these materials varies and variations in costs relating to these inputs can be significant.
Rest of the question

As previously requested, please expand your discussion of consolidated results and segment results to discuss these variations and how they impacted your operations from period to period.

CC answered
to the Staff’s comments, the Company respectfully advises the Staff that, to the extent variations in the pricing of ore materials, hydrocarbons and oil and gas have impacted our consolidated and segment results for the periods presented, this impact has been described for each segment on pages 59, 61, 62, 85, 93 and 97 and, other than as currently presented, Chemours has not experienced any significant variations in the pricing of ore materials, hydrocarbons or oil and gas that have impacted Chemours over such period.
Rest of the answer

Chemours is not currently aware of any known trends in the pricing of ore materials, hydrocarbons or oil and gas that would be expected to have a material impact on our results. However, the Company does acknowledge that variations in the cost of these items can be significant, and has provided descriptions of the risks to our operations associated with any potential significant price variations in these items on page 22 under “Risk Factors -

Price fluctuations in energy and raw materials could have a significant impact on our ability to sustain and grow earnings.”

Read in the reply
Overview
SEC asked (9)
We note your response to comment 16 of our letter dated January 14, 2015 and your revised disclosure. However, as previously requested, in light of the negative trend in net sales due to declines in selling prices in your fluoroproducts segment, during the nine months ended September 30, 2014 and the year ended December 31, 2013, please discuss any measures you are taking to address such declines and your
Rest of the question

expectations regarding future sales trends in your fluoroproducts segment. Refer to Item 303(a)(3)(ii) of Regulation S-K. Nine Months Ended September 30, 2014 compared to Nine Months Ended September 30, 2013,

CC answered
to the

Staff’s comment, the Company has revised its disclosure on pages 61–62.
Read in the reply
Overview
SEC asked (10)
We note your response to comment 18 of our letter dated January 14, 2015. If material, please expand your disclosure to discuss the impact that your customer’s election to exercise a buy-out option of a supply contract had on your cost of goods sold and/or your income before income taxes.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 58 to disclose the full year impact that the customer’s election to exercise a buy-out option of a supply contract had on the change in COGS. The election had an immaterial impact on income before income taxes.
Read in the reply
Liquidity and Capital Resources, page 61
SEC asked (11)
We note your supplemental response to comment 23 of our letter dated January 14, 2015 to the effect that you had no material commitments for capital expenditures at the end of 2014. We note that you are still in the process of expanding your Altamira plant. Please advise.
CC answered
The Company respectfully informs the Staff that it had no material commitments for capital expenditures as of December 31, 2014 or December 31, 2013. Contractual spend related to expansion of the Altamira plant historically contained cancellation provisions and therefore did not result in material commitments. The remaining costs to complete the expansion of Altamira are primarily external labor costs that also contain cancellation provisions and are only obligations as services are performed.
Read in the reply
Liquidity and Capital Resources, page 61
SEC asked (12)
We note your response to comment 24 of our letter dated January 14, 2015 and the revision to your disclosure; however, as requested in our prior comment, please specifically address that notwithstanding the fact that you have generated strong operating cash flows, there has been a significant negative trend in your cash flows from operations since 2011 which has continued through the nine months ended September 30,
Rest of the question

2014.

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 63–64 and 78.
Read in the reply
Cash Flows, page 61
SEC asked (13)
We note your response to comment 26 of our letter dated January 14, 2015. You indicate that the reduction in cash provided by operating activities resulting from net working capital changes related to inventory and trade accounts payable for raw materials was mainly the result of changes in timing and amount of ore purchased.
Rest of the question

As previously requested, please expand your disclosures to explain why the increase in accounts payable resulting from the timing and amount of ore purchased does not correlate to a similar increase in your inventory.

CC answered
to the Staff’s comment, the Company has revised its disclosure on page 64.
Read in the reply
Cash Flows, page 61
SEC asked (14)
We note your response to comment 27 of our letter dated January 14, 2015 and the revision to your registration statement. Please expand your discussion regarding the impact of working capital items on the decrease in cash provided by operating activities in 2013, as compared to 2012, to also address the decrease in cash resulting from the increase in your accounts and notes receivable – trade, net.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 64.
Read in the reply
Accounting Estimates, page 64 · Valuation of Assets, page 64
SEC asked (15)
We note your response to comment 28 of our letter dated January 14, 2015 as well as your revised disclosures. Please expand your disclosures to identify the lowest level(s) for which there are identifiable cash flows. We note that these levels vary. Furthermore, we note that you have not identified the level at which you assess goodwill for impairment.
Rest of the question

Please refer to ASC 360-10-35-23 through 35-25 and example 4 of ASC 360-10-55-35 for guidance.

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 67–68 and F-10–F-11.
Read in the reply
Quantitative and Qualitative Disclosures about Market Risk, page 71
SEC asked (16)
Please provide us with an analysis supporting your statement that “there are no quantitative disclosures required with respect to Item 305(a) of Regulation S-K.” We note that you provide quantitative disclosure regarding your hedging activities with regard to various risks on page F-15.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 73.

The Company respectfully advises the Staff on a supplemental basis that, as disclosed in the Company’s Form 10, the Company does not hold and has not held any derivative financial instruments, other financial instruments, or derivative commodity instruments, as referenced in Item 305 of Regulation S-K. The Company advises the Staff that the derivatives held by DuPont were not solely for the benefit of Chemours’ operations and were therefore excluded from the Combined Balance Sheets.
Rest of the answer

Accordingly, the detailed quantitative information required by

Item 305(a) of Regulation S-K was not required with respect to foreign currency or commodity exposure. The Company reviewed the “Questions and Answers About the New ‘Market Risk’ Disclosure

Rules” published by the SEC on July 31, 1997, specifically questions 10, 12, and 23, to conclude we are not subject to these disclosure requirements. When material financial instruments are entered into during 2015, the Company will update this item accordingly.

Read in the reply
Financial Statements, page F-1
SEC asked (17)
We note your response to comment 43 of our letter dated January 14 2015. Please expand your disclosures under the caption, “Formation of a Holding Company Prior to Distribution” on page 37, to clarify that Chemours Company, LLC had no or nominal operations during the period from February 18, 2014 through December 31, 2014.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 39.
Read in the reply
Note 8: Income Taxes, page F-19
SEC asked (18)
We note your expanded disclosures provided in response to comment 53 of our letter dated January 14, 2015. While you have broadly explained why there can be changes in the mix of income and loss amongst the various foreign jurisdictions in which you operate, you have not provided any specific information regarding your material tax jurisdictions and how changes in their pre-tax earnings impacted your effective tax
Rest of the question

rate. Please explain to us your consideration of providing this additional disclosure. Such disclosures would have the objective of providing information about the quality of, and potential variability of, your earnings and cash flow, so an investor can ascertain the likelihood that past performance is indicative of future performance. Note 17: Commitments and Contingent Liabilities, page F-27 (c) Litigation, page F-28

CC answered
to the Staff’s comment, the Company has revised its disclosure on page F-21.

Note 17: Commitments and Contingent Liabilities, page F-27

(c) Litigation, page F-28
Read in the reply
Note 8: Income Taxes, page F-19
SEC asked (19)
We note your response to comment 56 of our letter dated January 14, 2015, as well as your revised disclosures. Please revise your first paragraph to indicate whether it is probable, reasonable possible or remote that the potential resolution of your various proceedings will have a material adverse effect on Chemours combined financial position, liquidity, and results of operations.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 102–104 and F-29–F-31.
Read in the reply
Note 8: Income Taxes, page F-19
SEC asked (20)
We note your response to comment 57 of our letter dated January 14, 2015, as well as your revised disclosures and have the following additional comments:  As previously requested, please address this comment as it relates to your general litigation disclosure as well as your specific disclosure for asbestos; and  You indicate that it is reasonably possible that you could incur losses that will be significant to
Rest of the question

results of operations in the period recognized related to the other PFOA matters discussed. Please clarify what you mean by “significant”. (d) Environmental, page F-31

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages

102–104 and F-29–F-31.

(d) Environmental, page F-31
Read in the reply
Pompton Lakes, page F-32
SEC asked (21)
You indicate that it is reasonably possible that potential liability for remediation activities at Pompton Lakes could range up to $116 million and this could have a material impact on the liquidity of Chemours in the period recognized. Please expand your disclosure to clarify whether the additional reasonably possible loss could have a material adverse effect on your financial position and results of operations.
Rest of the question

Address this comment as it relates to your disclosures on page 70 as well.

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages

72 and F-33.

Additionally, with respect to the Pompton Lakes matter, we respectfully advise the Staff on a supplemental basis that our current accrual is $86 million as of December 31, 2014, and that our range of potential exposure is up to $116 million, resulting in a variance of $30 million. This could have a material impact on the liquidity of Chemours in the period recognized.
Rest of the answer

However, management does not believe that this would have a material adverse effect on Chemours combined financial position, liquidity and results of operations.

Read in the reply
Note 20: Segment Information, page F-35
SEC asked (22)
We note your response to comment 59 of our letter dated January 14, 2015. Please disclose the fact that you have not presented segment assets and the reason for its exclusion. Refer to ASC 280-10-50-26.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages F-35–F-36.

The Company respectfully advises the Staff on a supplemental basis that we have disclosed the measure of segment assets that is reviewed by our

Chief Operating Decision Maker (CODM), which is net assets by segment. Total assets by segment are not reviewed by, or provided to, the CODM and, as such, are not disclosed. Since we disclose the asset measure reviewed by our CODM for our reportable segments, we believe that we meet the disclosure requirements outlined in ASC 280-10-50-26.
Read in the reply
Exhibit 99.1 · Information Statement Summary, page 1
SEC asked (1)
Please refer to comment 3 of our letter dated January 14, 2015 and comment 3 of our letter dated February 26, 2015 and revise your disclosure consistent with our prior comments regarding your planned credit rating and environmental liabilities.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 10 and 11.
Read in the reply
Risk Factors, page 20 · As a substantial percentage of our operations are conducted internationally, and we plan to grow … page 21
SEC asked (2)
Please clarify your discussion of the risks posed to your business by your international expansion plans. We note your discussion of techniques used in selected countries to “enhance the overall cost position” of your Fluoroproducts segment, but it is unclear what risks these techniques present. Please refer to comment 6 of our letter dated January 14, 2015, and comment 5 of our letter dated February 26, 2015.
Rest of the question

Certain of the contracts to be transferred or assigned to us contain provisions requiring the consent… page 33

CC answered
to the Staff’s comment, the Company has revised its disclosure on page 24.

Certain of the contracts to be transferred or assigned to us contain provisions requiring the consent... page 33
Read in the reply
Risk Factors, page 20 · As a substantial percentage of our operations are conducted internationally, and we plan to grow … page 21
SEC asked (3)
Please revise to discuss the nature of the contracts that are the subject of this risk factor. Please provide similar revisions to your discussion of the contracts that you share with DuPont on page 151. Please refer to comment 10 of our letter dated January 14, 2015.
CC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, after further assessment of the applicable contracts, we have determined that this is not a material risk to our business. We have accordingly removed the risk factor.
Read in the reply
Your percentage of ownership in us may be diluted in the future, page 35
SEC asked (4)
We note your disclosure on page 121. Please disclose, here or elsewhere as appropriate, the amount of your stock that will be issuable upon the exercise of currently outstanding DuPont options held by your employees. Please refer to Item 201(a)(2)(i) of Regulation S-K and comment 11 of our letter dated January 14, 2015.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 38 and 130.
Read in the reply
Unaudited Pro Forma Combined Financial Statements, page 46
SEC asked (5)
Please be advised that we may have further comments when items that are currently blank are completed.
CC answered
to the Staff’s comment, we acknowledge that you may have further comments as items are completed.
Read in the reply
Unaudited Pro Forma Combined Financial Statements, page 46
SEC asked (6)
In Note 3 Summary of Significant Accounting Policies – Foreign Currency Translation on page F-14, you indicate that when Performance Chemicals operations are legally and operationally separated within DuPont, some of the newly created Chemours foreign entities will have their local currency as their functional currency.
Rest of the question

Please tell us what consideration you have given to reflecting these changes in functional currencies in your pro forma financial statements.

CC answered
The Company acknowledges the Staff’s comment and advises the

Staff that a pro forma presentation was considered for functional currency changes. The Company respectfully informs the Staff that some of the newly created Chemours foreign entities that are legally and operationally separated within DuPont have local currency as their functional currency. This occurred throughout the first quarter of 2015, as legal entities became operational. Functional currency designation is based on specific facts and circumstances that existed during the reporting period.
Rest of the answer

The Company may have made different operating decisions during the period, such as hedging programs if they had been local currency functional, such that any pro forma presentation would be hypothetical rather than factually supportable.

Therefore, the local functional currency will be reflected in the first quarter results, rather than reflected in a pro forma adjustment at 12/31/14.

Read in the reply
Notes to Unaudited Pro Forma Combined Financial Statements, page 49 · Note (A), page 49
SEC asked (7)
Please expand your footnote to quantify both the amount of the reduction in expense due to the exclusion of expenses associated with pension plans that will not be transferred to Chemours, as well as the amount of the increase in expense associated with the enhanced 401(k) plan.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 52.
Read in the reply
Note (D), page 49
SEC asked (8)
With reference to the information presented under the heading, “Treatment of Outstanding Equity Awards as of the Distribution Date” on page 121 as well as the guidance in ASC 718-20-35-6 and ASC 718-20-55, please confirm, if true, that the issuance of Chemours equity awards in connection with the distribution agreement will not result in incremental compensation cost.
Rest of the question

Otherwise, please address the need to provide a pro forma adjustment for any material incremental compensation cost.

CC answered
to the Staff’s comment, the Company has revised its disclosure on page 52.

Additionally, the Company respectfully advises the Staff, on a supplemental basis, that incremental compensation expense cannot be estimated as it is largely dependent on market factors used to ensure that the intrinsic value of the awards is maintained.
Read in the reply
Note (D), page 49
SEC asked (9)
We remind you to ensure that your footnote provides sufficient information to understand how the stock options and restricted stock awards reflected in diluted earnings per share were determined.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 52.
Read in the reply
Management’s Discussion and Analysis of Financial Condition and Results of Operations, page · Liquidity and Capital Resources, page 63
SEC asked (10)
Please describe in greater detail the manner in which the separation and your payment of $4 billion to DuPont, as well as the credit facilities that you will enter, will affect your liquidity and capital resources. Please refer to comment 22 and comment 25 of our letter dated January 14, 2015. Please ensure that you provide a thorough discussion of the changes in the mix and relative cost of your capital resources.
Rest of the question

Please refer to Item 303(a)(2)(ii) of Regulation S-K.

CC answered
to the Staff’s comment, the Company has revised its disclosure on pages 66–70.
Read in the reply
Capital Expenditures, page 65
SEC asked (11)
We note your response to comment 11 of our letter dated February 26, 2015. Please explain why you concluded that contracts with cancellation provisions do not create material commitments for capital expenditures that would otherwise trigger the requirement to provide disclosure under Item 303(a)(2) of Regulation S-K.
CC answered
Company respectfully advises the Staff that it has disclosed the annual capital expenditures related to the Altamira expansion on page 71, the expected expansion completion date on page 90, and the reduction expected in capital expenditures post completion on page 72. We believe that the cancellation provisions in our capital contracts allow the Company to consider its liquidity needs and adjust the timing of completion and amount of cash expenditures and therefore are not contractual obligations that create a firm commitment.
Rest of the answer

Given these disclosures we believe we have sufficiently provided the investor an understanding of the company’s plans for the timing and amount of expected cash outflows and the impact on near term liquidity.

Read in the reply
Contractual Obligations, page 66
SEC asked (12)
Expand your disclosures to clarify that your contractual obligations table does not include the $4 billion indebtedness and related interest expense which you will incur in conjunction with your separation from DuPont. Please also quantify your interest payments once the terms of the debt are determined.
CC answered
to the

Staff’s comment, the Company has revised its disclosure on page 73.
Read in the reply
Drinking Water Actions, page 103
SEC asked (13)
We refer to your response to our comment 36 of our letter dated January 14, 2015. To the extent that you do not intend on providing a rollforward of lawsuits at this time, please expand your disclosure to state, if true, that no claims have been dismissed, settled, or resolved during the periods presented.
CC answered
to the

Staff’s comment, the Company has revised its disclosure on pages 110–111 and F-31.
Read in the reply
Compensation and Discussion and Analysis, page 112
SEC asked (14)
Please provide us with the analysis that you relied upon in concluding that only one year of compensation disclosure is required in this filing. Please refer to Item 402(c)(1) of Regulation S-K, and Regulation S-K Compliance & Disclosure Interpretation 217.01.
CC answered
to the Staff’s comment, the Company respectfully advises the Staff that the instruction to Item 402(c) of Regulation S-K provides that “[i]nformation with respect to fiscal years prior to the last completed fiscal year will not be required if the registrant was not a reporting company pursuant to section 13(a) or 15(d) of the Exchange Act (15 U.S.C.
Rest of the answer

78m(a) or 78o(d)) at any time during that year, except that the registrant will be required to provide information for any such year if that information previously was required to be provided in response to a Commission filing requirement.” Accordingly, because Chemours was not a reporting company during 2014, in no case should more than one year of historical executive compensation disclosure be required here.

Regulation S-K Compliance & Disclosure Interpretation 217.01 describes circumstances in which one year of compensation disclosure might be appropriate in the spin-off context—i.e., circumstances in which a spin-off should be treated like an IPO and thus in which pursuant to the S-K 402 Instruction one year of disclosure could be required. The C&DI makes clear that the appropriate period for compensation disclosure is a facts and circumstances determination and that among the factors to be considered are whether the registrant was a reporting company or a separate division before the spin-off, as well as its continuity of management. For example, where before and after the spin-off the executive officers of the subsidiary were the same, provided the same type of services to the subsidiary and provided no services to the parent, C&DI 217.01 indicates that disclosure likely would be required but that, by contrast, where the parent company spins off a newly formed subsidiary consisting of portions of several different parts of the parent’s business and having new management, it is more likely that the spin-off could be treated as the IPO of a new “spun-off” registrant.

There is compelling reason to believe that the rationale of C&DI 217.01 does not require historical compensation disclosure under the circumstances here.

•

First, to separate Chemours from DuPont, DuPont must complete a series of complex internal reorganization transactions. Those transactions will require a series of strategic, structural and process realignment and restructuring actions within the Company’s operations. In addition, Chemours will be transferred not only the entities, assets and liabilities historically associated with DuPont’s performance chemicals business, but also certain additional assets and liabilities associated with the other DuPont businesses. Accordingly, the post-distribution business of Chemours is not entirely congruent with the pre-distribution business of DuPont’s performance chemicals business.

Second, there is at most limited continuity of management. Two of the Company’s executive officers—Mr. Newman, the Company’s Chief Financial Officer and Mrs. Albright, Senior Vice President of Human

Resources—are not historical DuPont employees and provided no prior services to DuPont. Those executive officers who are not new to DuPont historically were officers of DuPont, not Chemours, provided at least some services to the DuPont business other than the performance chemicals component and were compensated by DuPont, not Chemours. Moreover, the roles and responsibilities of the legacy DuPont executives will be significantly different after the distribution. For example,

Mr. Vergnano, who previously was an Executive Vice President within DuPont, will be providing very different services to the Company as he will be responsible for leading all Company business units and functions while managing relationships with all its internal and external stakeholders; Mr. Vanlancker previously managed the combined chemical solutions and fluoroproducts operations within DuPont, whereas the scope of his new role generally will be fluoroproducts only; and Messrs.

Vanlancker and Chong, who both previously were DuPont officers reporting indirectly to the DuPont CEO, will have materially different roles as they will have significantly expanded duties incorporating oversight of support activity previously performed within separate DuPont corporate functions, responsibility for plant, supply chain and engineering activities, and a role in setting the strategic direction for the entire Chemours business, not just the particular component with which they were previously associated.

Under such circumstances we believe that no historical compensation disclosure is required under a C&DI 217.01 analysis. Note that C&DI 217.03 supports that conclusion: it explains that where, as here, a subsidiary of a public company is going public and where, as here in respect of at least those officers who were previously employed by DuPont, the officers of the subsidiary previously were officers of the parent and in some cases all of the work that they did for the parent related to the subsidiary, the registration statement of the subsidiary would not be required to include compensation previously awarded by the parent corporation.

The Company has nonetheless provided one year of historical compensation disclosure with a view toward providing information that some stockholders may find useful. The Compensation Discussion and Analysis makes clear, however, that historical compensation paid by DuPont is not necessarily indicative of the compensation that the Company will pay going forward.

Read in the reply
2014 STIP Performance and Payout Factors, page 124
SEC asked (15)
We note that the STIP program for 2014 was based on pre-established company goals. Item 402(b) of Regulation S-K requires that you disclose all previously established goals and discuss how the incentive compensation actually awarded reflects those goals.
Rest of the question

While your disclosure reflects the payout factors for the components of your STIP, it is unclear what targets you had for your various metrics and what levels of performance were achieved. Please revise. Please also clarify how “business units” are defined, and what business unit each executive was evaluated in relation to.

CC answered
to the Staff’s comment, we respectfully advise the Staff that we do not believe Item 402(b) of Regulation S-K requires us to disclose the targets used by DuPont in its compensation programs. The DuPont targets, goals and performance that were used for the 2014 STIP payouts are not relevant to Chemours as a standalone company. Several examples of how the targets and goals are not relevant follow: One of our NEOs did not participate in the STIP program in 2014 and, as a result, did not have either a target or actual award with regard to the STIP.
Rest of the answer

The STIP business unit factors for two of our NEO’s were based on the performance of all 12 DuPont business units and are therefore unrelated to performance of Chemours. Additionally, the business role of one of the NEOs has changed due to the reorganization at Chemours and, as a result, he will lead a different segment of Chemours and, thus, will not have the same STIP business unit factor going forward. All leaders who were employed by DuPont for a significant portion of 2014 had a corporate factor based on total DuPont results, which is unrelated to the Chemours or the Chemours business units. The Chemours legal and business structure was not established until the first quarter of 2015, which would have been the first opportunity to establish targets and actual awards based on

Chemours business performance. In future filings with the SEC, Chemours will include a discussion of performance targets, if any, used in its compensation program if material to Chemours’ executive compensation programs.

This Registration Statement on Form 10 relates to information for Chemours. After the separation, Chemours will be an independent company, and we expect its shares will be listed on the New York Stock Exchange. The Chemours Board and Compensation Committee will review and set the compensation policy for Chemours executive officers, including performance targets for its STIP, which may be materially different from that of DuPont. As such, we do not believe DuPont’s STIP is material information to an investor of Chemours. When targets are established, Chemours will disclose its executive compensation programs, including targets and actual results as compared to those targets.

Additionally, we have revised the disclosure on page 133 to clarify the definition of

“business units” and the relevant business unit used in evaluating each executive’s performance.

Read in the reply
Security Ownership of Directors and Executive Officers, page 147
SEC asked (16)
Please disclose the DuPont holdings of your executive officers. Refer to comment 39 of our letter dated January 14, 2015 and Item 403(b) of Regulation S-K.
CC answered
to the Staff’s comment, the Company has revised its disclosure on page 157.
Read in the reply
Financial Statements, page F-1 · Combined Balance Sheets, page F-4
SEC asked (17)
We remind you to reflect the intended cash dividend to DuPont on a pro forma basis alongside your most recent historical balance sheet as provided by SAB Topic 1:B:3.
CC answered
to the Staff’s comment, the Company has revised its disclosure on pages F-4 and F-15.
Read in the reply
Exhibit 99.1 · General
SEC asked (1)
Please revise your registration statement to provide updated financial statements and related disclosures as required by Rule 3-12 of Regulation S-X.
CC answered

No numbered answer found in the reply. Read the reply ↗

Unaudited Pro Forma Combined Financial Statements, page 49
SEC asked (2)
We note your response to comment 6 of our letter dated May 5, 2015. Please disclose the fact that your pro forma financial statements do not reflect any changes in the functional currencies of certain of your newly created foreign entities.
CC answered
We acknowledge the Staff’s comment and have revised the disclosure on page 47.
Read in the reply
Notes E and F, page 52
SEC asked (3)
Please better explain how you have established $200 million of cash and cash equivalents. In this regard, we note your statement in Note F that you have not retained any cash as a result of the financing transactions.
CC answered
We acknowledge the Staff’s comment and respectfully advise the Staff that the Master Separation

Agreement Section 2.13 Cash Management; Cash Adjustment, Subsection (a) describes a cash reference level of $200 million. DuPont intends to initiate steps, prior to the distribution date, that will result in a cash and cash equivalents balance at Chemours of at least $200 million as of the distribution date. We have also revised our disclosure on page 70.
Read in the reply
Notes E and F, page 52
SEC asked (4)
Please separately present the inflows and outflows of the financing transactions you have reflected in Note F. In doing so, please better explain the nature of the “distribution inkind of 2015 Notes.”
CC answered
We acknowledge the Staff’s comment and have revised the disclosure on pages 51-52.
Read in the reply
Notes G and I, page 53
SEC asked (5)
Please better explain the determination of the $57 million adjustment to accumulated other comprehensive income discussed in Note G, as well the $26 million adjustment to other comprehensive income discussed in Note I. In this regard, we note a $57 million adjustment reflected on your pro forma balance sheet.
CC answered
Staff’s comment and respectfully inform the Staff on a supplemental basis that the $57 million adjustment to Accumulated Other Comprehensive Income represents Chemours’ portion of the multi-employer pension plans Accumulated Other

Comprehensive Income, which is a proration based on the projected benefit obligation calculated using Chemours’ census data.
Rest of the answer

We relied on the guidance provided in ASC 845-10-55 in evaluating the treatment of the pension plans.

We further acknowledge the Staff’s comment regarding the $26 million adjustment and inform the Staff on a supplemental basis that this adjustment represents the net impact of the pension plan net liability of $83 million less the related Accumulated Other Comprehensive Income of $57 million through the elimination of DuPont Company Net Investment and adjustments to Capital in excess of par.

This adjustment is shown in our Interim Pro Forma Statements Note I at $16 million, which is comprised of the net pension liability of $85 million less the related Accumulated Other Comprehensive Income, net of tax of $44 million and related net deferred tax assets of $25 million.

Read in the reply
Financial Statements, page F-1 · Combined Balance Sheets, page F-4
SEC asked (6)
Please revise your unaudited pro forma footnote reference to say “Note 3.”
CC answered
We acknowledge the Staff’s comment and have revised the disclosure on page F-40.
Read in the reply
Note 21: Subsequent Events, page F-38
SEC asked (7)
Please expand your disclosures to indicate whether the date through which subsequent events were evaluated is the date the financial statements were issued or the date the financial statements were available to be issued as required by ASC 855-10-50-1.
CC answered
We acknowledge the Staff’s comment and have revised the disclosure on page

F-36 for the Annual Combined Financial Statements.
Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 22 letters filed since 2015-02-12. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.